Doxylamine succinate pharma grade API is the succinic acid salt of doxylamine, an ethanolamine-derived H₁-antagonist used in oral solid and injectable dosage forms. The molecular formula is C₁₇H₂₂N₂O·C₄H₆O₄ and the relative molecular mass is 388.46 g/mol. The CAS number for the succinate salt is 562-10-7. The substance is supplied as a white or almost white crystalline powder and is described in the USP–NF and Ph. Eur. monographs as doxylamine succinate or doxylamine hydrogen succinate. It is not interchangeable with doxylamine base or doxylamine hydrochloride without dose conversion. The API is offered in three physical models against the same pharmacopeial assay boundary: a direct-compression grade with controlled particle-size distribution and low fines, a fine-particle grade for granulation or suspension applications, and a sterile injectable grade with bacterial endotoxin and particulate control.

The principal clinical use of doxylamine succinate is as an antihistamine sedative and, in combination with pyridoxine hydrochloride, for nausea and vomiting of pregnancy. In oral solid form, the salt is formulated in strengths of 10 mg or 25 mg; the approved delayed-release combination product uses 10 mg doxylamine succinate with 10 mg pyridoxine hydrochloride. The succinate salt is preferred over the free base because it is a stoichiometric crystalline salt that can be milled, blended, and compressed without the handling problems of a low-melting base. For injectable use, the same salt is dissolved in Water for Injection, but the oral-grade API cannot be automatically substituted for a parenteral-grade material unless endotoxin and particulate requirements are met.

Compendial specification boundaries for doxylamine succinate bulk API

The release specification is defined by the current USP–NF monograph for Doxylamine Succinate and the corresponding Ph. Eur. monograph, with additional product-specific particle-size and microbial requirements for pharmaceutical processing. Representative release attributes are listed below; the current monograph text governs official limits where applicable.

For tablet and capsule operations, the main process bottleneck is not chemical purity but particulate and flow variability. A direct-compression blend containing 25 mg doxylamine succinate in a 150–200 mg core is typically manufactured by charging a diffusion blender to 60–70% capacity and blending for 15–20 minutes with colloidal silicon dioxide before lubrication. Magnesium stearate is added in the final 2–5 minutes at 0.25–1.0 wt% to limit over-lubrication. Content uniformity is confirmed using the acceptance value in USP <905>. Because the active-to-excipient ratio is approximately 1:6 to 1:8, API aggregates above 250 µm produce superpotent and subpotent zones if the lot is not screened through a 500 µm sieve before blending.

What limits direct compression at the 25 mg unit strength?

Direct compression is limited primarily by powder flow and segregation rather than solubility. If the API lot has a Hausner ratio above 1.35 or a Carr index above 25%, tablet weight variability increases on a high-speed rotary press, and compact hardness measured on a linear speed production press may fall outside the target range of 40–80 N. A direct-compression grade is therefore milled to a D90 of 150–250 µm and a D10 above 40 µm; the full particle-size distribution is monitored by laser diffraction per USP <429>. Tablets are compressed at 20–30 kN depending on tooling geometry, with friability maintained below 0.8% using USP <1216>. Disintegration in water at 37°C according to USP <701> is typically complete within 30 minutes for immediate-release formulations. A validated dissolution method in 900 mL of 0.1 N hydrochloric acid at 37°C using USP <711> Apparatus 2 at 50 rpm is commonly employed for oral immediate-release forms; a Q value of 80% at 30 minutes is a typical development target rather than a compendial specification unless claimed.

For strengths below 25 mg, ordered mixing or geometric dilution is required. Random mixing alone may fail USP <905> if API agglomerates are not deagglomerated. Production-scale experience indicates that punch filming on rotary presses is observed when the blend moisture exceeds 2.0% w/w and the lubrication time is below 2 minutes. The corrective action is dry storage below 60% RH and controlled final blending with magnesium stearate.

The succinate counterion changes base-equivalent dose and handling relative to the hydrochloride

Doxylamine succinate contains 1 mol of succinic acid per 1 mol of doxylamine base. The base-equivalent fraction is therefore the ratio of doxylamine base molecular mass to succinate salt molecular mass: 270.37 g/mol divided by 388.46 g/mol, or 0.696. A 25 mg succinate salt dose provides 17.4 mg doxylamine base. Doxylamine hydrochloride has a molecular mass of 306.83 g/mol and a base-equivalent fraction of 0.881; a 25 mg hydrochloride dose provides 22.0 mg doxylamine base. This difference is critical in reformulation, label claim, and bioequivalence studies. The succinate salt is generally selected for oral dosage forms where the crystalline character supports direct compression and where the higher salt mass permits a larger excipient mass; however, published comparative dynamic vapour sorption and intrinsic dissolution rate data for the succinate and hydrochloride salts are limited. Salt-form interchange without a controlled dose-calculation exercise is therefore unacceptable.

Doxylamine succinate also differs from other ethanolamine antihistamines such as diphenhydramine hydrochloride in the side-chain structure. Doxylamine contains a pyridine ring and an oxygen-containing ethylamine side chain, whereas diphenhydramine contains two phenyl rings. This structural difference changes chromatographic retention, UV detection wavelength, photodegradation pathways, and the compatibility envelope with acidic or oxidative excipients. The dose-equivalence comparison between products is not a therapeutic equivalence statement and must be assessed through the applicable regulatory pathway.

Capsule filling uses the same direct-compression blend as tablets but with glidant level at the upper end of the range because flow into dosator or tamping-pin stations on automatic capsule machines is more sensitive to floodability. A fill weight of 180–220 mg in a size 3 hard gelatin capsule containing 25 mg doxylamine succinate requires a tapped density of 0.50–0.70 g/mL when tested by USP <616>; if tapped density falls below 0.45 g/mL, fill weight variation increases and the process may exceed the capsule weight-acceptance limit. Published data for this specific formulation configuration are limited, so these are development starting ranges rather than pharmacopeial requirements.

When the API is specified for delayed-release granules or coated multiparticulates

Delayed-release oral forms of doxylamine succinate require granulation before the coating step because unagglomerated API particles are too fine and have poor mechanical adhesion for direct film-coating. A high-shear granulator with a 10 L bowl and chopper at 1500 rpm can be used to agglomerate the API with lactose monohydrate and a povidone binder solution. Wet mass is discharged at a power-consumption set point rather than at a fixed time; the substrate is then dried in a fluid-bed dryer at inlet air 50–60°C until loss on drying is below 2.0%. The dried granules are sieved through 850 µm before coating. Top-spray application of an aqueous methacrylic acid copolymer dispersion to a weight gain of 8–12% provides enteric protection. Release is confirmed using a two-stage dissolution test per USP <711> Apparatus 1 at 100 rpm with 0.1 N hydrochloric acid for 2 h, followed by pH 6.8 phosphate buffer for 45 min; a typical product-specific criterion is not more than 10% release in acid stage and at least 80% release after 45 min in buffer. These acceptance criteria are product-specific because no public compendial dissolution test exists for doxylamine succinate delayed-release granules; method validation follows ICH Q2(R1). Published endpoint data for doxylamine succinate high-shear granulation are limited, and process parameters must be qualified at production scale.

Injectable-grade processing and bacterial endotoxin control

Injectable-grade doxylamine succinate is not interchangeable with oral grade. The bulk API is tested for bacterial endotoxins and visible particulates before release. For aqueous injectable solutions, the API is dissolved in Water for Injection at a product-specified concentration. If terminal sterilization is required, the solution pH is adjusted to the acidic range where the tertiary amine remains protonated, and the filled vials are autoclaved. No public terminal-sterilization validation cycle specific to doxylamine succinate is available; therefore a product-specific cycle must be qualified. Aseptic filtration through a 0.22 µm polyvinylidene fluoride membrane with filter integrity testing per ASTM F838-20 is used when terminal sterilization is not feasible.

Bacterial endotoxin limit is derived from the endotoxin limit equation in USP <85>: endotoxin limit = K/M, where K is 5 EU/kg for most parenteral products and M is the maximum bolus dose in mg/kg. If the maximum bolus dose of doxylamine succinate is taken as 10 mg in a 70 kg patient, M is 0.14 mg/kg, giving a calculated limit of 35.7 EU/mg. Manufacturer specifications for sterile API are often set below the calculated limit, and batch-specific endotoxin release must be justified by the finished-product risk assessment. Particulate matter in injectable solutions is evaluated by light obscuration per USP <788>; for small-volume injections, the acceptance limits are not more than 6000 particles per container at ≥10 µm and not more than 600 particles per container at ≥25 µm.

Long-term stability of the dry API should be assessed in closed containers at 25°C/60% RH for 36 months with accelerated conditions at 40°C/75% RH for 6 months under ICH Q1A(R2). Because doxylamine succinate contains a tertiary amine, oxidative degradation should be evaluated in forced-degradation studies; contact with strong oxidizing agents, strong acids, or strong bases should be controlled. For aqueous injectable development, pH-dependent photostability and oxygen headspace effects require evaluation according to ICH Q1B and ICH Q1A(R2). In bulk storage, high humidity may produce soft aggregates; if lumps are observed, the API should be delumped through a 500 µm conical mill at low speed and remilled only if the particle-size specification is exceeded.